Informatics
This section features DDW articles around informatics in drug discovery.
Page 28 to 42 of 55 |   < PREVIOUS PAGE   NEXT PAGE >
In Silico Structure-based Drug Design - Shifting the bottleneck? By Dr Jonathan Heal Drug Discovery
The use of in silico methods in drug design has grown significantly in popularity over the past couple of years. Indeed many pharma companies have already adopted some type of virtual screening capability to complement HTS methods. Will we eventually see this technology replacing HTS and removing the burden of discovery chemistry?

Read More

Predictive chemoinformatics applications to the pharmaceutical industry By Dr Leslie J. Browne and Laurie L.Taylor
While significant advances in chemoinformatics present tremendous opportunities to improve human health, the future of chemoinformatics in the pharmaceutical industry is not without significant challenges.

Read More

Proteomatics - New information resources for proteomics By Dr David J Parry-Smith and Dr David S Bailey
Proteomics is the science of understanding protein architectures at a supramolecular level, whereas the realm of understanding the organisation of biological information in its totality belongs to bioinformatics.

Read More

Implementation or algorithm? The value of Bioinformatics By Dr Christopher Hogue
Recently the value of bioinformatics has been questioned. The value can be proven but are there enough qualified and professionally trained people who know how to build good bioinformatics tools?

Read More

From raw data in the laboratory to information availability in the enterprise By Dieter Kreusel
If pharmaceutical or biotechnology companies could measure their success merely on the volume of raw data accumulated from screening assays and pre-clinical testing, they would be basking in the glow of unprecedented success.

Read More

Data Mining in the pharmaceutical industry By Dr Robert D. Small and Herbert A. Edelstein
A research-based pharmaceutical company is a data accumulating wonder. More than in any other industry, success is predicated on the collection, processing and exploitation of that data. This is not always recognised and often not planned for by large pharmaceutical companies.

Read More

The promise of pharmacogenetics and pharmacogenomics By Dr Tim Peakman and Dr Steve Arlington
Within the next 10 years the benefits of pharmacogenetics and pharmacogenomics will inevitably outweigh the disadvantages. But what are the commercial and legal implications for the pharmaceutical industry especially for companies who have lead candidates ready to enter development?

Read More

Transforming Data Into Better Healthcare By Dr Jens Hoefkens
The healthcare industry is drowning in data for which it lacks established data analysis processes. This situation exists despite the fact that appropriate and efficient data analysis processes are keys to better decision-making and enhanced healthcare therapies, which can potentially result in multi-billion dollar savings.

Read More

Healthcare and Life Sciences undergoing disruptive change by linked data and semantic technologies By Hans Constandt
From early days the sharing of knowledge has been one of the main forces driving science and innovation. Yet latterly, the pharmaceutical industry with its fear of loss of intellectual property has stalled the engine that has given so many beneficial outcomes. This article argues that the semantic web offers the hope of a new golden age of drug discovery.

Read More

The Benefits of Biological Modelling By Gordon Webster
The enormous challenge posed by the complexity of biological systems represents a potential intellectual impasse to researchers and threatens to stall future progress in basic biology and healthcare.

Read More

High Content Screening - The next challenge: effective data mining and exploration By Dr Kurt Zingler and Dr Stephan Heyse
The use of high content screening within HTS is growing and with many past hurdles now overcome, the need for effective tools for data analysis is becoming paramount.

Read More

Data Overflow Progress in Automating and Streamlining Data By Peer Staehler
The genomic world moves faster and faster. The pool of data has exploded exponentially in the past few years due to the growing knowledge about the relevance of genomic findings for medicine and the environment. Like all other developing industries, the trend in genomics is about producing more in a shorter amount of time with a higher quality.

Read More

Enterprise ELNs as a Foundation for Preclinical Drug Development By Simon Beaulah, Dr Paul Denny- Gouldson and Dr Scott Weiss
To have real business impact within preclinical drug development, Enterprise ELNs (Electronic Laboratory Notebooks) must provide a secure, scalable and searchable data management backbone across all disciplines focused on development of both small and large molecules, in compliant and non-compliant environments.

Read More

Integrating Computational Methods and Drug Discovery - Avoiding pitfalls in chemical space By Alexandre Ismail and Professor Philippe Manivet
The immensity of the task in discovering suitable molecules for development among the vast number which are theoretically available is well stated. With 90% of potentially efficacious compounds failing at latter stages, the earlier toxic candidates are dropped from the development process the greater the amount of time and money saved.

Read More

Informatics
Page 28 to 42 of 55 |   < PREVIOUS PAGE   NEXT PAGE >